These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 29858280

  • 1. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.
    Ueda Y, Miwa T, Gullipalli D, Sato S, Ito D, Kim H, Palmer M, Song WC.
    J Am Soc Nephrol; 2018 Jul; 29(7):1928-1937. PubMed ID: 29858280
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The development of atypical hemolytic uremic syndrome depends on complement C5.
    de Jorge EG, Macor P, Paixão-Cavalcante D, Rose KL, Tedesco F, Cook HT, Botto M, Pickering MC.
    J Am Soc Nephrol; 2011 Jan; 22(1):137-45. PubMed ID: 21148255
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.
    Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Córdoba SR, Botto M.
    J Exp Med; 2007 Jun 11; 204(6):1249-56. PubMed ID: 17517971
    [Abstract] [Full Text] [Related]

  • 9. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
    Dekkers G, Brouwer MC, Jeremiasse J, Kamp A, Biggs RM, van Mierlo G, Lauder S, Katti S, Kuijpers TW, Rispens T, Jongerius I.
    J Immunol; 2020 Oct 01; 205(7):1778-1786. PubMed ID: 32848031
    [Abstract] [Full Text] [Related]

  • 10. Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy.
    Vernon KA, Ruseva MM, Cook HT, Botto M, Malik TH, Pickering MC.
    J Am Soc Nephrol; 2016 May 01; 27(5):1334-42. PubMed ID: 26374608
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
    Michels MAHM, Volokhina EB, van de Kar NCAJ, van den Heuvel LPWJ.
    Pediatr Nephrol; 2019 Aug 01; 34(8):1349-1367. PubMed ID: 30141176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
    Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.
    Front Immunol; 2019 Aug 01; 10():853. PubMed ID: 31118930
    [Abstract] [Full Text] [Related]

  • 15. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ.
    J Immunol; 2018 Apr 01; 200(7):2464-2478. PubMed ID: 29500241
    [Abstract] [Full Text] [Related]

  • 16. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.
    Westra D, Volokhina EB, van der Molen RG, van der Velden TJ, Jeronimus-Klaasen A, Goertz J, Gracchi V, Dorresteijn EM, Bouts AH, Keijzer-Veen MG, van Wijk JA, Bakker JA, Roos A, van den Heuvel LP, van de Kar NC.
    Pediatr Nephrol; 2017 Feb 01; 32(2):297-309. PubMed ID: 27718086
    [Abstract] [Full Text] [Related]

  • 17. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
    Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.
    Am J Kidney Dis; 2017 Dec 01; 70(6):770-777. PubMed ID: 28821363
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera.
    Pouw RB, Brouwer MC, de Gast M, van Beek AE, van den Heuvel LP, Schmidt CQ, van der Ende A, Sánchez-Corral P, Kuijpers TW, Wouters D.
    Blood Adv; 2019 Feb 26; 3(4):621-632. PubMed ID: 30804016
    [Abstract] [Full Text] [Related]

  • 20. Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.
    Miwa T, Sato S, Gullipalli D, Nangaku M, Song WC.
    J Immunol; 2013 Apr 01; 190(7):3552-9. PubMed ID: 23427256
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.